• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Study on the migration capacity of type 2 innate lymphocytes in inflammatory skin diseases

Research Project

Project/Area Number 20K17331
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 53050:Dermatology-related
Research InstitutionHyogo Medical University

Principal Investigator

Nagai Makoto  兵庫医科大学, 医学部, 講師 (30791545)

Project Period (FY) 2020-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2022: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2021: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2020: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords2型自然リンパ球 / ILC2 / アトピー性皮膚炎 / IL-33 / 2型自然リンパ球 / ILC2
Outline of Research at the Start

IL-33は2型自然リンパ球を活性化する物質で、皮膚にIL-33が過剰になる遺伝子改変マウス(hK14mIL33tg)はアトピー性皮膚炎になります。しかし、ILC2が皮膚からリンパ節に移動するかどうかは、不明でした。この研究では珊瑚(キクメイシ)の遺伝子をマウスの細胞に入れることで皮膚ILC2の動態を可視化し、皮膚病変部から所属リンパ節にILC2などの免疫細胞が遊走する動態を明かにします。本研究によって、ADにおけるILC2のリンパ節への遊走能とその意義が明らかになることで、アレルギー性疾患の新規治療法の開発や創薬に繋がることが期待されます。

Outline of Final Research Achievements

We previously generated a transgenic mouse line expressing skin-specific IL-33 (IL33tg mice) and showed that IL-33 elicits group 2 innate lymphoid cell (ILC2)-dependent atopic dermatitis-like skin inflammation.We sorted ILC2s from the skin and draining lymph nodes of IL33tg mice and analyzed their transcriptomes using the single-cell RNA sequencing technique, which revealed that the skin ILC2s had split into two clusters: circulating ILC2 and skin-resident ILC2. We tracked ILC2 migration using IL33tg-Kikume Green-Red mice. Exposing the IL33tg-Kikume Green-Red mice’s inflamed skin to violet light allowed us to label the circulating ILC2s in their skin and track the ILC2 migration from the skin to the draining lymph nodes.

Academic Significance and Societal Importance of the Research Achievements

IL-33は2型自然リンパ球を活性化する物質で、皮膚にIL-33が過剰になる遺伝子改変マウス(hK14mIL33tg)はアトピー性皮膚炎になります。しかし、ILC2が皮膚からリンパ節に移動するかどうかは、不明でした。この研究では珊瑚(キクメイシ)の遺伝子をマウスの細胞に入れることで皮膚ILC2の動態を可視化し、皮膚病変部から所属リンパ節にILC2などの免疫細胞が遊走する動態を明かにします。本研究によって、ADにおけるILC2のリンパ節への遊走能とその意義が明らかになることで、アレルギー性疾患の新規治療法の開発や創薬に繋がることが期待されます。

Report

(4 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (12 results)

All 2023 2022 2021 2020

All Journal Article (8 results) (of which Peer Reviewed: 8 results,  Open Access: 7 results) Presentation (4 results) (of which Int'l Joint Research: 3 results)

  • [Journal Article] IL-33-induced keratoconjunctivitis is mediated by group 2 innate lymphoid cells in mice2023

    • Author(s)
      Hosotani Y, Yasuda K, Nagai M, Yamanishi K, Kanazawa N, Gomi Fumi, Imai Y
    • Journal Title

      Allergology International

      Volume: 72 Issue: 2 Pages: 324-331

    • DOI

      10.1016/j.alit.2022.10.003

    • ISSN
      1323-8930, 1440-1592
    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis2022

    • Author(s)
      Kita Kanako、Imai Yasutomo、Nagai Makoto、Natsuaki Masaru、Kanazawa Nobuo
    • Journal Title

      Journal of Cutaneous Immunology and Allergy

      Volume: - Issue: 3 Pages: 1-2

    • DOI

      10.1002/cia2.12282

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Evaluation of long-term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real-world clinical practice2022

    • Author(s)
      Kunimoto M, Imai Y*, Matsutani M, Nakatani-Kusakabe M, Nagai M, Natsuaki M, Yamanishi K, Kanazawa N
    • Journal Title

      J Cutan Immunol Allergy

      Volume: 5 Issue: 2 Pages: 69-71

    • DOI

      10.1002/cia2.12212

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Monitoring Cellular Movement with Photoconvertible Fluorescent Protein and Single-Cell RNA Sequencing Reveals Cutaneous Group 2 Innate Lymphoid Cell Subtypes, Circulating ILC2 and Skin-Resident ILC22021

    • Author(s)
      Nakatani-Kusakabe Minori、Yasuda Koubun、Tomura Michio、Nagai Makoto、Yamanishi Kiyofumi、Kuroda Etsushi、Kanazawa Nobuo、Imai Yasutomo
    • Journal Title

      JID Innovations

      Volume: 1 Issue: 3 Pages: 100035-100035

    • DOI

      10.1016/j.xjidi.2021.100035

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Dupilumab effects on innate lymphoid cell and Th cell populations in patients with atopic dermatitis2021

    • Author(s)
      Imai Y, Kusakabe M, Nagai M, Yasuda K, Yamanishi K.
    • Journal Title

      JID Innovations

      Volume: 1 Issue: 1 Pages: 100003-100003

    • DOI

      10.1016/j.xjidi.2021.100003

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice2021

    • Author(s)
      Matsutani M, Imai Y, Inoue Y, Nakatani-Kusakabe M, Natsuaki M, Yamanishi K, Kanazawa N
    • Journal Title

      J Dermatol

      Volume: 48 Issue: 10 Pages: 1564-1568

    • DOI

      10.1111/1346-8138.16039

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Switching to ixekizumab improves adalimumab‐induced interstitial lung disease in patients with psoriatic arthritis: A case report2021

    • Author(s)
      Hayashi H, Kusakabe M, Nagai M, Imai Y, Yamanishi K
    • Journal Title

      J Cutan Immunol Allergy

      Volume: 4 Issue: 1 Pages: 22-23

    • DOI

      10.1002/cia2.12146

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] レボフロキサシンによるアナフ ィラキシーの1例2020

    • Author(s)
      藤本 真由, 夏秋 優, 北 佳奈 子, 井上 裕香子, 永井 諒, 今 井 康友, 山西 清文
    • Journal Title

      皮膚の科学

      Volume: 19 Pages: 244-250

    • NAID

      130008006031

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Presentation] The role of IL-33/gdT/IL17 signal axis in the pathogenesis of skin inflammation2022

    • Author(s)
      Hongjin Li, Yasutomo Imai, Teruasa Murata, Nobuo Kanazawa
    • Organizer
      The 47th Annual Meeting of the Japanese Society for Investigative Dermatology
    • Related Report
      2022 Annual Research Report
  • [Presentation] Identification of serum biomarkers predicting the therapeutic effect of dupilumab in atopic dermatitis by a targeted metabolomics approach2021

    • Author(s)
      Miyamoto Shoko, Nishiumi Shin, Matsutani Masako, Nagai Makoto, Yamanishi Kiyofumi, Kanazawa Nobuo, Imai Yasutomo
    • Organizer
      The 46th Annual Meeting of the Japanese Society for Investigative Dermatology
    • Related Report
      2021 Research-status Report
    • Int'l Joint Research
  • [Presentation] Dupilumab’s Effects on Circulating Group 2 Innate Lymphoid Cell and T Helper Type 2 Cell Populations in Patients with Atopic Dermatitis2020

    • Author(s)
      Imai Y, Kusakabe M, Nagai M, Inoue Y, Natsuaki M, Yamanishi K
    • Organizer
      The 45th Annual Meeting of the Japanese Society for Investigative Dermatology
    • Related Report
      2020 Research-status Report
    • Int'l Joint Research
  • [Presentation] Single-Cell RNA Sequencing Reveals Novel Cutaneous Group 2 Innate Lymphoid Cell Subtypes, Circulating ILC2, and Skin-Resident ILC22020

    • Author(s)
      Kusakabe M, Imai Y, Nagai M, Yasuda K, Kuroda E, Tomura M, Yamanishi K
    • Organizer
      The 45th Annual Meeting of the Japanese Society for Investigative Dermatology
    • Related Report
      2020 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2020-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi